| Description |
Iron(III) complexes with 2-(3-hydroxypropylamino)-6-benzylaniino-9-isopropylpurine (Bohemin, HL1), in its protonized form, of the composition (H+HL1)(2)[FeCl5]. 2H(2)O (1), (H+HL1)(2)[FeCl5]. 3H(2)O (2) have been prepared by two different routes. A new way for synthesis of copper(II) complex with 6-(2-chlorobenzylamino)purine (HL2), [Cu-2(mu -Cl)(2)(mu -HL2)(2)(HL2)(2)Cl-2]. 2H(2)O (3), together with the preparation of copper(II) complex with 6-(3-chlorobenzylamino)purine (HL3), [Cu-2(mu -Cl)(2)(mu -HL3)(2)Cl-2] (4), is also reported. The characterization have been based on elemental analysis, electronic, infrared, ES + mass and Fe-57 Mossbauer spectra, conductivity data and magnetic susceptibility temperature measurements over the 4.5-300 K for 1-3, and 35-300 K for 4. temperature range, respectively. Molecular structure of an electroneutral form of the HL2 ligand, (HL2. 2H(2)O), and a protonized form of the HL3 ligand, (H+HL3-Cl), have been determined by a single-crystal X-ray analysis. A mononuclear trigonal-bipyramidal (for 1 and 2), binuclear octahedral (for 3) and binuclear trigonal-bipyramidal (for 4) structures of the complexes were proposed mainly on the basis of spectral and magnetic properties. An S = 3/2-5/2 spin-admixed state in 1 and 2 was found to be related to the presence of [FeCl5](2-) (S = 3/2) and [FeCl5(H2O)](2-) (S = 5/2) complex anions in I and 2, as found by Fe-57 Mossbauer spectroscopy. Cytotoxic activity of the complexes was determined by a calcein AM assay and IC50 values were also estimated. For testing, human malignant melanoma cell line G-361. human osteogenic sarcoma cell line HOS, human chronic myelogenous leukaemia K-562 and human breast adenocarcinoma cell line MCF7 were used. The inhibition of p34(cdc2) kinase by the complexes I and 2, which is known to be one of the important mechanisms responsible for cytotoxicity of cytokinin-derived compounds, was also studied.
|